Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (DE:5CV)
XETRA:5CV
CureVac (5CV) Stock Price & Analysis
6 Followers
5CV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.11 - €9.10
Previous Close€3.16
Volume88.79K
Average Volume (3M)212.69K
Market Cap
€748.76M
Enterprise Value€388.13M
Total Cash (Recent Filing)$402.45M
Total Debt (Recent Filing)$41.82M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 15, 2024EPS Estimate
-€0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding223,988,675
10 Day Avg. Volume181,787
30 Day Avg. Volume212,693
Standard Deviation0.27
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.49
Price to Sales (P/S)12.92
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.38
Enterprise Value/Gross Profit-5.50
Enterprise Value/Ebitda-4.32
Forecast
1Y Price Target
€9.15Price Target Upside189.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
CureVac News
PremiumCompany Announcements
CureVac Announces Key Patent Litigation Dates
PremiumCompany Announcements
CureVac Shareholders Approve Key Resolutions
PremiumCompany Announcements
CureVac Shareholders Approve Board AppointmentsBulls Say, Bears Say
Bulls Say
Financial StabilityThe 30% workforce reduction, along with cost reduction announced at 4Q23 earnings, extend cash runway into 2028, providing greater financial stability.
Strategic CollaborationGSK takes full ownership of COVID-19 and flu mRNA vaccines, providing €400M upfront to CureVac, plus additional potential milestones and royalties, strengthening CureVac's financial position.
Strategic RestructuringCureVac’s strategic restructuring focuses resources on the most advanced wholly-owned pipeline assets, potentially accelerating progress in key areas.
Bears Say
Balance SheetBalance sheet pressure implies the company will have a year or less of cash by the time of meaningful combination vaccine or oncology pipeline data.
Competitive PositioningCompetitive positioning is unclear in a declining commercial market, and Phase 2 flu data disclosure lacked quantitative results, making comparison with competitors challenging.
EarningsCureVac reported 1Q24 results missing our and consensus estimates, ending the quarter with cash of €300M due to continued costs related to the first-gen COVID-19 vaccine CVnCoV.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
1.18% Mutual Funds
1.26% Other Institutional Investors
97.56% Public Companies and
Individual Investors
5CV FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was €2.11 and its highest was €9.10 in the past 12 months.
What is CureVac’s market cap?
Currently, no data Available
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Aug 15, 2024 which is in 28 days.
How were CureVac’s earnings last quarter?
Currently, no data Available
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is -€0.27.
How many shares outstanding does CureVac have?
CureVac has 224,305,680 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is RA Capital Management. It holds CureVac’s shares valued at 6M.
---
CureVac Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.15 (189.60% Upside)
€9.15 (189.60% Upside)
Blogger Sentiment
Bearish
DE:5CV Sentiment 67%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.20%
12-Months-Change
Fundamentals
Return on Equity
-47.08%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
CureVac
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
---
5CV Company Deck
---
5CV Earnings Call
Q4 2024
0:00 / 0:00
---
5CV Stock 12 Month Forecast
Average Price Target
€9.15
▲(189.60% Upside)
Technical Analysis
Best Analysts Covering 5CV
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-34.61%
reiterated a buy rating 8 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -34.61% per trade.
---